Form 4: NKGen Biotech CEO Awarded 2 Million Stock Options

NKGen Biotech's CEO, Paul Y. Song, was granted 2 million stock options under the company's 2023 Equity Incentive Plan.

Summary

• Paul Y. Song, the Chief Executive Officer of NKGen Biotech, was granted 2,000,000 stock options on December 6, 2024.
• The options were granted under the company's 2023 Equity Incentive Plan.
• The exercise price for each option is $0.438.
• The options vest in 48 equal monthly installments, starting on January 6, 2025, and ending on December 6, 2028.
• Vesting is contingent upon Mr. Song's continued service with NKGen Biotech.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The stock option grant aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The value of the options is dependent on the future performance of NKGen Biotech's stock price.
• If the CEO leaves the company before the options fully vest, he may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next four years, contingent on the CEO's continued service.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 48 months is typical for such grants, ensuring long-term commitment.
• The exercise price of $0.438 is dependent on the current stock price of NKGen Biotech and is not directly comparable without knowing the stock price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity incentive plan, CEO, Paul Y. Song, NKGen Biotech, executive compensation, vesting